United States - English - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2)], - with gastric retention [see warnings and precautions (5.3)], - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)], and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2)]. risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period of or

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2) ] , - with gastric retention [see warnings and precautions (5.3) ] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5 )] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2) ] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the per

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2) ] , - with gastric retention [see warnings and precautions (5.3) ] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5 )] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2) ] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the per

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2) ] , - with gastric retention [see warnings and precautions (5.3) ] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5 )] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2) ] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the per

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2) ] , - with gastric retention [see warnings and precautions (5.3) ] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5 )] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2) ] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the per

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2) ] , - with gastric retention [see warnings and precautions (5.3) ] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5 )] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2) ] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the per

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: - with urinary retention [see warnings and precautions (5.2)] , - with gastric retention [see warnings and precautions (5.3)] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2)] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice d

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2)], - with gastric retention [see warnings and precautions (5.3)], - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema

United States - English - NLM (National Library of Medicine)

proficient rx lp - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period of organogenesis at a dose resulting in 1.2 times the systemic exposure at the maximum recommended human dose (mrhd) of 10 mg/day. however, administration of doses 3.6 times and greater than the mrhd during organogenesis produced maternal toxicity in the pregnant mice and resulted in developmental toxicity and reduced fetal body weights in offspring [see data]. in the u.s. general population, the estimated background risk of major birth de

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: • with urinary retention [ see warnings and precautions ( 5.2) ], • with gastric retention [ see warnings and precautions ( 5.3) ], • with uncontrolled narrow-angle glaucoma [ see warnings and precautions ( 5.5) ], and • who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingradients in solifenacin succinate. reported adverse reactions have included anaphylaxis and angioedema [ see adverse reactions ( 6.2) ]. risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcome